Lessons to take home from CATIE

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 523-525

  Carpenter, William T ^a   Buchanan, Robert W ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DYSPHORIA; HIGH RISK POPULATION; METABOLIC SYNDROME X; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOSIS; SCHIZOPHRENIA; SHORT SURVEY; STROKE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; METABOLIC SYNDROME X; SCHIZOPHRENIA;

EID: 50849131245     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.59.5.523     Document Type: Short Survey

References (13)

1. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
2. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al: The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin 32:214-219, 2006
3. Carpenter WT Jr, Heinrichs DW, Wagman AMI: Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry 145:578-583, 1988
4. Carpenter WT, Gold JM: Atypical antipsychotic drugs improve cognition in schizophrenia. Biological Psychiatry 53:265-270, 2003
5. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
6. Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal 172:1703-1711, 2005
7. Jones PB, Davies L, Barnes TR, et al: Randomized controlled trial of effect on quality of life of second-generation vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
8. Lewis SW, Barnes TRE, Davies L, et al: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32:715-723, 2006
9. Keefe RS, Bilder RM, Davis, SM, et al: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 64:633-647, 2007
10. Buchanan RW, Davis M, Goff D, et al: A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin 31:5-19, 2005
11. Rosenheck RA, Leslie DL, Busch S, et al: Rethinking antipsychotic formulary policy. Schizophrenia Bulletin 34:375-380, 2008
12. Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 163:2090-2095, 2006
13. Rosenheck R, Swartz M, McEvoy J, et al: Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research 7: 103-111, 2007